More than $20 billion in major cardiovascular drug revenues will be exposed to patent expiration in the next three to five years, according to a report by business intelligence firm Cutting Edge Information. The report, entitled "Cardiovascular Marketing: Budgets, Staffing and Strategy," available online, highlights the necessity of being able to adapt to the rapid and constant change seen in the pharmaceutical cardiovascular market.
Pharmaceutical companies spend more to support a cardiovascular compound's development and commercialization than they do on any other therapeutic products. Among top drug makers, sales from cardiovascular medicines may contribute anywhere from 20% to 50% of annual pharmaceutical revenues. Because of the great expense of developing cardiovascular drugs, top pharmaceutical companies are shifting away from developing new anti-anginal medicines for cardiovascular diseases. On average, new cardiovascular drug research is receiving only $83 million per company, according to a report by business intelligence firm Cutting Edge Information ( http://www.pharmacardio.com/ ).